Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

143 – Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24

Background Prospective trials have not previously compared the efficacy of boosting with the ancestral/monovalent mRNA vaccine (WA-1) versus a bivalent ancestral plus BA.4/BA.5-targeted vaccine in African countries, with high HIV and SARS-CoV-2 seroprevalence. Methods The second phase of CoVPN 3008 (Ubuntu trial) was a double-blind randomized trial in 7 countries, among people with HIV (PWH)…

104 – HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial

Background ImmTAV® are soluble bispecific T cell engagers that kill virus-infected cells presenting extremely low target peptide-HLA levels. IMC-M113V (GAGxCD3) is the first HIV ImmTAV in the clinic; a single dose study demonstrated safety and biological activity in antiretroviral therapy (ART)-suppressed PLWH. We investigated the effect of multiple ascending doses of IMC-M113V on HIV reservoir…

102 – Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art

Background Recent studies suggest that HIV-1 reservoir cells are subject to immune selection pressure, but the host immune responses that are able to engage and target viral reservoir cells are unknown. To infer mechanisms underlying immune selection activity against viral reservoir cells, we conducted a parallel, longitudinal phenotypic evaluation of HIV-1 reservoir cells and antiviral…

138 – Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells

Background Due to its high binding affinity to HIV capsid (p24), the first-in-class capsid inhibitor Lenacapavir (LEN) might display a post-integration effect on capsid production. However, this effect and its underlying mechanism, as well as its clinical impact on LEN-treated individuals, have yet to be characterized. Methods The post-integration effect of increasing concentrations of LEN…

133 – Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses

Background BACKGROUND Persistence of the HIV reservoir during antiretroviral therapy is a major obstacle to curing the infection. This reservoir can be established in the hyperacute stage of the infection, and lymphoid tissue analysis of this stage revealed HIV infection of resting T cells. Given that the HIV reservoir resides in resting CD4 T cells,…

136 – Visualizing the Cell Biology of HIV Latency and Reactivation

Background Studies using the Jurkat T-cell model have identified numerous factors crucial for initiating HIV-1 transcription. However, a significant limitation of transformed cells is their inability to replicate the transitions between active effector cells and quiescent memory T cells, which are the key drivers of HIV latency in vivo.  Methods We use refined primary cell…

105 – Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI

Background Antiretroviral therapy (ART) can reduce morbidity and mortality but does not eradicate HIV. Developing new therapies that induce HIV remission is crucial to end the epidemic. African women bear a disproportionate burden of the global epidemic yet are rarely included in clinical trials. We conducted a phase 2a HIV cure study to evaluate the…

135 – Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore

Background The nuclear import of HIV-1 into the host nucleus marks a milestone of the viral infection, making it a potential drug target for effective prophylaxis and treatment. However, understanding this process has been challenged by its dynamic nature and the scarcity of HIV-1 cores in infected cells.  Methods To elucidate the mechanisms underlying the…

100 – 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART

Background Residual viremia (RV) persists despite years of effective ART due to the daily activation of latently infected cells. Some people on long-term ART develop nonsuppressible viremia (NSV), characterized by persistently detectable HIV RNA that complicates clinical care, raising concerns for virological failure and HIV transmission. Recent work from our group and others showed that…

134 – Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly

Background The CARD8 inflammasome is a key driver of innate immune responses to HIV-1. CARD8, containing HIV-1 protease (PR) cleavage sites, responds to PR upon enforced NNRTI-induced dimerization of the viral Gag-Pol polyprotein and premature PR activation. In the absence of antiretrovirals, the apparent lack of CARD8 activation during HIV-1 assembly along with the observation…